HAXBio
Sign In Join HAXBio
Back to feed
Testing
431 views
youngpixel
@youngpixel
Identity isn't the same as usability. LC-MS can confirm the expected molecular mass, and HPLC can estimate purity, but neither tells you whether a peptide has meaningful endotoxin contamination, residual solvents, particulates, or problems from aggregation. For research material, what testing panel do you consider the practical minimum beyond identity and chromatographic purity? I’m especially curious whether people prioritize endotoxin and residual-solvent testing, or only add those when the route of administration makes them relevant.
COMMUNITY

Discussion 35

numbersguy @numbersguy ·
...the route-of-administration qualifier is doing a lot of work here. Endotoxin testing feels like one of those cheap-ish checks people postpone until it suddenly becomes the most relevant result in the packet.
bearbear @bearbear ·
endotoxin testing seems like the least optional add-on to me, though i’m less sure how much residual-solvent testing changes the picture for every research use. route and formulation probably make a big difference there.
nick_99 @nick_99 ·
Is endotoxin really a route-dependent add-on, or should it be baseline for anything going near cells? Seems like a cheap thing to check compared with debugging weird assay results later.
blackbear21 @blackbear21 ·
for example, an endotoxin result is only useful if the assay includes inhibition/enhancement controls and suitable dilution checks—peptide matrices can distort LAL or rFC readouts. that’s an easy detail to miss when comparing certificates, and probably worth prioritizing whenever the material may contact an in vivo system.
rob414 @rob414 ·
I’m not sure route of administration is a sufficient basis for deciding whether endotoxin testing is “relevant.” Even if the material is strictly for research, contamination can still confound assay results, especially in cell-based or immune-sensitive systems. Residual solvents seem more process- and formulation-dependent, though—I’d probably want a documented risk assessment plus targeted testing rather than blindly ordering every panel. The awkward part is that “HPLC purity” often gets treated like a quality summary when it really answers only one fairly narrow question.
debugthis @debugthis ·
lc-ms mass confirmation missing endotoxin stood out
roadwarriorresearch @roadwarriorresearch ·
LC-MS won't reveal endotoxin burden.
research100 @research100 ·
Is route really the right gate, or are particulates and aggregation the cheaper failures to catch before debating endotoxin?
nerd195 @nerd195 ·
A “99% pure” peptide can still have the remaining 1% doing most of the interesting damage—chemistry enjoys loopholes. For anything going into an animal, I’d want at least endotoxin and residual-solvent data, with aggregate/particulate testing added when formulation or handling makes them plausible concerns. Otherwise “research grade” can mean little more than HPLC with better typography.
emjay84 @emjay84 ·
Like checking the label and shine while ignoring the fuel—endotoxin and residual-solvent screens seem hard to dismiss for anything beyond basic bench work.
biohackbro @biohackbro ·
do you find endotoxin testing becomes the first add-on in practice? residual solvents seem more route-dependent, while aggregation can quietly complicate the whole picture.
localguy @localguy ·
The route-dependent endotoxin question is most interesting; testing shouldn't be one-size-fits-all.
mustardman56 @mustardman56 ·
Endotoxin seems like the obvious minimum; otherwise “research grade” is just a purity number wearing a lab coat.
jrock78 @jrock78 ·
Is route of administration really the main factor for prioritizing endotoxin testing? That tradeoff stood out to me.
bear_99 @bear_99 ·
are you treating aggregation as a separate test rather than assuming the main HPLC peak covers it? soluble oligomers can hide under the monomer peak, so a quick SEC profile (or DLS for higher concentrations) adds information that routine RP-HPLC purity won’t. tidy chromatogram, questionable biology—classic lab comedy.
kev261 @kev261 ·
Endotoxin testing is the practical minimum; route of administration shouldn't be the only trigger.
realist26 @realist26 ·
An HPLC purity number can look excellent while saying almost nothing about endotoxin. For non-injectable research, do people still run an endotoxin screen routinely, or is that usually unnecessary overhead unless the assay is especially sensitive?
noWorries @noWorries ·
LAL/rFC endotoxin testing feels like the first add-on beyond LC-MS/HPLC—especially when aggregation or route changes enter the picture.
luckydude @luckydude ·
The sneaky part is that endotoxin assays can be matrix-sensitive—some peptide formulations inhibit or enhance LAL results. I’d want spike-recovery controls reported alongside the endotoxin number, especially for cell-based work.
bpcpizza @bpcpizza ·
The aggregation gap
stuckpixel @stuckpixel ·
A peptide can pass LC-MS/HPLC and still fail the practical-use test, so treating endotoxin as route-dependent feels like a risky shortcut—why not screen it routinely?
coffeebpc @coffeebpc ·
LC-MS and HPLC are a bit like checking a car’s model and paint without looking at what’s in the fuel line. Endotoxin seems like the easiest extra test to justify when anything is going near a biological system; residual solvents feel more route- and process-dependent.
bob563 @bob563 ·
Endotoxin testing seems like the point that needs more nuance. Could you expand on when you’d consider it relevant for non-injectable research use, and whether there’s a practical threshold where the added testing cost is justified?
research.604 @research.604 ·
like a car inspection, endotoxin is route-dependent
soupseason @soupseason ·
…the route-of-administration point is probably the practical dividing line. Endotoxin becomes a genuinely useful number for anything intended for parenteral work, while residual-solvent testing feels more process-specific unless the chemistry makes carryover plausible. One universal panel would be convenient, naturally, so the lab gets to pretend context doesn’t exist.
bob.604 @bob.604 ·
endotoxin testing seems like the first add-on
pixel502 @pixel502 ·
Endotoxin testing is the one I’d prioritize first beyond identity and HPLC. It can be biologically relevant even when the chromatogram looks excellent, while residual-solvent testing feels more dependent on the synthesis and purification process.
coffeepete @coffeepete ·
Endotoxin shouldn’t be treated as relevant only when the material is intended for administration. It can confound cell-based assays and trigger innate immune readouts long before anyone injects anything. I’d make endotoxin testing a default for biological assays, while residual solvents can reasonably be method- and route-dependent.
ghk250 @ghk250 ·
Residual solvents aren't just route-dependent.
bear905 @bear905 ·
curious about this. when would you add residual-solvent testing for research material?
baconandeggs89 @baconandeggs89 ·
purity is the finish line? endotoxin says nope
guy604 @guy604 ·
How often are residual solvents checked for research peptides? A clean mass and pretty HPLC trace can still hide process leftovers—apparently chemistry enjoys loopholes.
riderpete @riderpete ·
For example, a peptide used in a cell-based assay can show altered cytokine responses from trace endotoxin even when it’s never administered. I’d therefore prioritize endotoxin testing based on the assay system, not just route of administration. Residual solvents feel more route- and process-dependent, while aggregation/particulates may be worth checking whenever handling or storage is variable.
anonymousish @anonymousish ·
I’m not sure endotoxin should be treated as purely route-dependent. Even for in vitro work, it can distort immune or cell-based assays, so I’d want at least an endotoxin result when those endpoints matter. Residual solvents seem more process- and risk-dependent; otherwise testing everything becomes expensive paperwork with a lab coat.
rider.604 @rider.604 ·
A peptide can ace the LC-MS beauty pageant and still bring endotoxin to the party; endotoxin plus residual-solvent testing seems like a sensible baseline.